Avanos Medical Inc (NYSE:AVNS) Expected to Post Earnings of $0.32 Per Share

Wall Street analysts expect Avanos Medical Inc (NYSE:AVNS) to report earnings per share (EPS) of $0.32 for the current quarter, Zacks reports. Three analysts have issued estimates for Avanos Medical’s earnings. The lowest EPS estimate is $0.31 and the highest is $0.34. Avanos Medical posted earnings per share of $0.37 during the same quarter last year, which indicates a negative year-over-year growth rate of 13.5%. The business is scheduled to issue its next earnings results on Tuesday, November 5th.

According to Zacks, analysts expect that Avanos Medical will report full-year earnings of $1.20 per share for the current fiscal year, with EPS estimates ranging from $1.18 to $1.23. For the next financial year, analysts forecast that the company will post earnings of $1.65 per share, with EPS estimates ranging from $1.49 to $1.80. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that follow Avanos Medical.

Avanos Medical (NYSE:AVNS) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.25 by $0.03. The firm had revenue of $172.20 million during the quarter, compared to the consensus estimate of $172.02 million. Avanos Medical had a negative net margin of 3.92% and a positive return on equity of 4.18%. The firm’s revenue was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.20 earnings per share.



A number of equities analysts have commented on AVNS shares. Stifel Nicolaus set a $45.00 price objective on shares of Avanos Medical and gave the stock a “buy” rating in a report on Wednesday, August 7th. ValuEngine raised shares of Avanos Medical from a “hold” rating to a “buy” rating in a report on Tuesday, July 2nd. Raymond James decreased their price objective on shares of Avanos Medical from $57.00 to $48.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. Zacks Investment Research downgraded shares of Avanos Medical from a “hold” rating to a “sell” rating in a report on Monday, May 6th. Finally, Morgan Stanley set a $47.00 price objective on shares of Avanos Medical and gave the stock a “sell” rating in a report on Wednesday, May 8th. Three equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $57.50.

Avanos Medical stock traded up $0.42 during mid-day trading on Tuesday, reaching $36.55. The company’s stock had a trading volume of 226,200 shares, compared to its average volume of 340,787. The firm has a market cap of $1.72 billion, a price-to-earnings ratio of 31.97 and a beta of 1.46. The business has a 50 day moving average price of $40.87 and a 200-day moving average price of $43.00. The company has a current ratio of 3.06, a quick ratio of 2.35 and a debt-to-equity ratio of 0.25. Avanos Medical has a twelve month low of $35.21 and a twelve month high of $72.96.

In related news, CEO Joseph Fralin Woody bought 3,500 shares of the business’s stock in a transaction on Thursday, May 30th. The shares were bought at an average cost of $39.95 per share, for a total transaction of $139,825.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.57% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Financial Gravity Wealth Inc. lifted its stake in Avanos Medical by 2,303.4% in the second quarter. Financial Gravity Wealth Inc. now owns 697 shares of the company’s stock valued at $30,000 after buying an additional 668 shares during the last quarter. Trustcore Financial Services LLC bought a new stake in Avanos Medical in the second quarter valued at $46,000. Advisory Services Network LLC lifted its stake in Avanos Medical by 39.7% in the second quarter. Advisory Services Network LLC now owns 1,203 shares of the company’s stock valued at $53,000 after buying an additional 342 shares during the last quarter. Steward Partners Investment Advisory LLC bought a new stake in Avanos Medical in the second quarter valued at $64,000. Finally, Skandinaviska Enskilda Banken AB publ bought a new stake in Avanos Medical in the second quarter valued at $69,000. Institutional investors own 92.24% of the company’s stock.

Avanos Medical Company Profile

Avanos Medical, Inc operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life worldwide. It provides a portfolio of products focuses on respiratory and digestive health; pain management solutions; and minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes.

Read More: What is the CBOE Russell 2000® Volatility Index?

Get a free copy of the Zacks research report on Avanos Medical (AVNS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.